Literature DB >> 17848877

Methicillin-resistant Staphylococcus aureus outbreak in an intensive care nursery: potential for interinstitutional spread.

Jay R McDonald1, Charlene M Carriker, Brian C Pien, Jane V Trinh, John J Engemann, Lizzie J Harrell, Mary A Oden, David T Tanaka, Ronald N Goldberg, Daniel J Sexton, Keith S Kaye.   

Abstract

BACKGROUND: After surveillance surveys documented the absence of methicillin-resistant Staphylococcus aureus (MRSA) in our intensive care nursery, an outbreak of MRSA infection occurred there during a 7-month period in 2005.
METHODS: Control measures included reinforcement of hand hygiene and contact precautions procedures. Active surveillance cultures were obtained on all neonates, including interinstitutional transfers. A cohort unit was dedicated exclusively for neonates with MRSA. Pulsed-field gel electrophoresis was performed on isolates to determine relatedness. We surveyed transferring hospitals to evaluate MRSA activity and surveillance practices in their nurseries.
RESULTS: Twenty-five neonates were colonized with MRSA; 9 of these had clinical infections. Isolates from 18 of 21 neonates from this outbreak and 4 neonates from a previous cluster were identical, including 1 isolate obtained upon transfer from another institution. Admission and discharge logs from a 9-month period showed that 127 of 460 admissions (27.6%) were admitted from 34 hospitals, and 247 of 460 (53.7%) were discharged to 32 hospitals. Among 30 transferring hospitals responding to our survey, MRSA activity occurred in 2 of 28 (7%) level 1 nurseries, 4 of 11 (36%) level 2 nurseries and 6 of 10 (60%) level 3 nurseries. Nine of the 30 hospitals (30%) performed some active surveillance.
CONCLUSIONS: Interinstitutional transfer can play a role in the initiation and propagation of MRSA outbreaks in neonatal nurseries. The burden of MRSA in area nurseries and the rate of transfers affect the potential for interhospital spread of MRSA and may justify changes in policy regarding surveillance for MRSA and communication between hospitals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848877     DOI: 10.1097/INF.0b013e3180616ce4

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  The potential economic value of a Staphylococcus aureus vaccine for neonates.

Authors:  Bruce Y Lee; Paul J Ufberg; Rachel R Bailey; Ann E Wiringa; Kenneth J Smith; Andrew J Nowalk; Conor Higgins; Angela R Wateska; Robert R Muder
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

2.  Modeling the spread of methicillin-resistant Staphylococcus aureus (MRSA) outbreaks throughout the hospitals in Orange County, California.

Authors:  Bruce Y Lee; Sarah M McGlone; Kim F Wong; S Levent Yilmaz; Taliser R Avery; Yeohan Song; Richard Christie; Stephen Eubank; Shawn T Brown; Joshua M Epstein; Jon I Parker; Donald S Burke; Richard Platt; Susan S Huang
Journal:  Infect Control Hosp Epidemiol       Date:  2011-06       Impact factor: 3.254

3.  Effect of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit on total hospital cost.

Authors:  Eric D Schultz; David T Tanaka; Ronald N Goldberg; Daniel K Benjamin; P Brian Smith
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

4.  Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA.

Authors:  Jingru Meng; Hui Wang; Zheng Hou; Tao Chen; Jingguo Fu; Xue Ma; Gonghao He; Xiaoyan Xue; Min Jia; Xiaoxing Luo
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

5.  First outbreak with MRSA in a Danish neonatal intensive care unit: risk factors and control procedures.

Authors:  Benedicte Grenness Utke Ramsing; Magnus Arpi; Erik Arthur Andersen; Niels Knabe; Dorthe Mogensen; Dorte Buhl; Henrik Westh; Christian Ostergaard
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.